Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 bi
We talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future of genomic medicines and how healthcare systems may need to adapt to
Two pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious alliance to develop new cancer therapies.
The trial of Sangamo’s gene-editing treatment for a rare and debilitating disease has got off to a good start, with no safety concerns reported so far.
